Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets.

Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Blood (Impact Factor: 9.78). 06/2008; 112(3):848-55. DOI: 10.1182/blood-2007-11-122598
Source: PubMed

ABSTRACT Resolvin E1 (RvE1) is an omega-3 eicosapentaenoic acid (EPA)-derived lipid mediator generated during resolution of inflammation and in human vasculature via leukocyte-endothelial cell interactions. RvE1 possesses anti-inflammatory and proresolving actions. Here, we report that RvE1 in human whole blood rapidly regulates leukocyte expression of adhesion molecules. RvE1 in the 10- to 100-nM range stimulated L-selectin shedding, while reducing CD18 expression in both neutrophils and monocytes. When added to whole blood, RvE1 did not stimulate reactive oxygen species by either neutrophils or monocytes, nor did it directly stimulate cytokine/chemokine production in heparinized blood. Intravital microscopy (IVM) demonstrated that RvE1 rapidly reduced leukocyte rolling (approximately 40%) in venules of mice. In human platelet-rich plasma (PRP), RvE1 selectively blocked both ADP-stimulated and thromboxane receptor agonist U46619-stimulated platelet aggregation in a concentration-dependent manner. In contrast, Delta 6,14-trans-RvE1 isomer was inactive. RvE1 did not block collagen-stimulated aggregation, and regulation of ADP-induced platelet aggregation was not further enhanced with aspirin treatment. These results indicate RvE1 is a potent modulator of leukocytes as well as selective platelet responses in blood and PRP, respectively. Moreover, the results demonstrate novel agonist-specific antiplatelet actions of RvE1 that are potent and may underlie some of the beneficial actions of EPA in humans.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ischemia/reperfusion (I/R) injury can occur in consequence of myocardial infarction, stroke and multiple organ failure, the most prevalent cause of death in critically ill patients. I/R injury encompass impairment of endothelial dependent relaxation, increase in macromolecular perme-ability and leukocyte-endothelium interactions. Polyunsat-urated fatty acids (n-3 PUFA), such as eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) found in fish oil have several anti-inflammatory properties and their potential benefits against I/R injury were investigated using the hamster cheek pouch prepara-tion before and after ischemia. Before the experiments, hamsters were treated orally with saline, olive oil, fish oil and triacylglycerol (TAG) and ethyl ester (EE) forms of EPA and DHA at different daily doses for 14 days. Fish oil restored the arteriolar diameter to pre ischemic values during reperfusion. At onset and during reperfusion, Fish oil and DHA TAG significantly reduced the number of rolling leukocytes compared to saline and olive oil treatments. Fish oil, EPA TAG and DHA TAG significantly prevented the rise on leukocyte adhesion compared to saline. Fish oil (44.83 ± 3.02 leaks/cm 2), EPA TAG (31.67 ± 2.65 leaks/ cm 2), DHA TAG (41.14 ± 3.63 leaks/cm 2), and EPA EE (30.63 ± 2.25 leaks/cm 2), but not DHA EE (73.17 ± 2.82 leaks/cm 2) prevented the increase in macromolecular permeability compared to saline and olive oil (134.80 ± 1.49 and 121.00 ± 4.93 leaks/cm 2 , respectively). On the basis of our findings, we may conclude that consumption of n-3 polyunsaturated fatty acids, especially in the triacyl-glycerol form, could be a promising therapy to prevent microvascular damage induced by ischemia/reperfusion and its consequent clinical sequelae. Keywords n-3 PUFA Á Microvascular diameter Á Leukocyte rolling/sticking Á Macromolecular permeability Á Ischemia/reperfusion Á Hamster cheek pouch List of Abbreviations ANOVA Analysis of variance AP-1 Activator protein-1 ARA Arachidonic acid (20:4n-6) BK Ca Large conductance Ca 2? -dependent K ? channels COX Cyclooxygenase DHA Docosahexaenoic acid (22:6n-3) EE Ethyl ester EPA Eicosapentaenoic acid (20:5n-3) FITC Fluorescein isothiocyanate ICAM-1 Intercellular adhesion molecule-1 IL Interleukin I/R Ischemia/reperfusion LOX Lipoxygenase LT Leukotriene(s) MUFA Monounsaturated fatty acid(s) NF-jB Nuclear factor-jB NADPH Nicotinamide adenine dinucleotide phosphate PAF Platelet activating factor PUFA Polyunsaturated fatty acid(s) Resolvins Resolution phase interaction products ROS Reactive oxygen species TAG Triacylglycerol TNF-a Tumor necrosis factor-a VCAM-1 Vascular cell adhesion molecule-1
    Lipids. 10/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Numerous epidemiological studies and clinical trials have reported the health benefits of omega-3 polyunsaturated fatty acids (PUFA), including a lower risk of coronary heart diseases. This review mainly focuses on the effects of alpha-linolenic (ALA), eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids on some risk factors associated with atherothrombosis, including platelet activation, plasma lipid concentrations and oxidative modification of low-density lipoproteins (LDL). Special focus is given to the effects of marine PUFA on the formation of eicosanoids and docosanoids, and to the bioactive properties of some oxygenated metabolites of omega-3 PUFA produced by cyclooxygenases and lipoxygenases. The antioxidant effects of marine omega-3 PUFA at low concentrations and the pro-oxidant effects of DHA at high concentrations on the redox status of platelets and LDL are highlighted. Non enzymatic peroxidation end-products deriving from omega-3 PUFA such as hydroxy-hexenals, neuroketals and EPA-derived isoprostanes are also considered in relation to atherosclerosis. This article is part of a Special Issue on “Oxygenated metabolism of polyunsaturated fatty acids, analytical issues, and pathophysiological relevance.” This article is part of a Special Issue entitled "Oxygenated metabolism of PUFA: analysis and biological relevance.
    Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 09/2014; · 4.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate whether liver steatosis reduction due to a six-month dietary intervention results in significant changes in the concentrations of fatty acids. A group of 35 Caucasian individuals diagnosed with different levels of steatosis were prospectively enrolled in the present study. Analysis of the fatty acid profiles was performed according to changes in liver steatosis (liver steatosis reduction by one or two degrees) after a six-month dietary intervention. The diet helped reduce body mass in obese and overweight patients, and stabilize both glycemia and dyslipidemia. Fatty acids were extracted according to the Folch method and analyzed by gas chromatography. This study showed significant changes in fatty acid profiles in patients who had reduced liver steatosis by one as well as two degrees. A reduction in liver steatosis by one degree caused a significant increase in the level of the n-3 family: eicosapentaenoic acid (P < 0.055), docosapentaenoic acid-C 22:5 (P < 0.05) and docosahexaenoic acid (P < 0.05). A reduction in liver steatosis by two degrees caused a significant decrease in serum palmitoleic acid-C 16:1 (P < 0.05). Liver steatosis reduction is associated with changes in fatty acid profiles, and these changes may reflect an alteration in fatty acid synthesis and metabolism. These findings may help better understand regression of nonalcoholic fatty liver disease.
    World journal of gastroenterology : WJG. 01/2015; 21(1):301-10.

Full-text (2 Sources)

Available from
Jun 5, 2014